<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211757</url>
  </required_header>
  <id_info>
    <org_study_id>01-0294</org_study_id>
    <secondary_id>1R21NS043979</secondary_id>
    <nct_id>NCT00211757</nct_id>
  </id_info>
  <brief_title>Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism</brief_title>
  <official_title>Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <brief_summary>
    <textblock>
      The study is designed to assess the efficacy of treatment with divalproex sodium (DS) vs.&#xD;
      placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview&#xD;
      (ADI) criteria. Currently, there are no FDA-approved treatments for this disorder, although&#xD;
      behavioral and educational therapies and a variety of medications may play a role in the&#xD;
      management of some autistic symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares divalproex sodium and placebo in the treatment of autistic disorder.&#xD;
      Twenty six child or adolescent outpatients, with age ranges from 5-17, will be randomized&#xD;
      into a 12-week double-blind, placebo-controlled parallel treatment study. During the 12&#xD;
      weeks, patients will be monitored by the treating psychiatrist and assessed by an independent&#xD;
      evaluator (IE). The IE will perform study assessments while remaining blind to medication&#xD;
      regimens (including possible tapering) as well as any side effects. Study assessments will be&#xD;
      administered at designated time points&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Improvement on the Clinical Global Impression</measure>
    <time_frame>Baseline to end of study (week 15)</time_frame>
    <description>The CGI-I is a 7-point improvement scale. Ratings of 1 or 2 (responders) indicate a substantial reduction in symptoms. A rating of 3 (minimally improved) on the CGI is defined as a slight symptomatic improvement that is not deemed clinically significant; patients with such an improvement were not considered responders. Two versions of this test were used, one focused on irritability (primary outcome measure) and a general version CGI-I-autism focused on all symptoms including core symptom domains. The CGI-I irritability took into consideration the scores from the ABC-Irritability subscale, the OAS-M aggression and irritability subscales and information from open-ended questioning related to the degree of interference, nature, and range of behavioral problems at school and at home</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores</measure>
    <time_frame>Baseline and End of Study (week 15)</time_frame>
    <description>The Aberrant Behavior Checklist is designed to objectively identify five behavior sub scales through observation by the primary caregiver: irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech. The ABC was filled out by parents on a scale from 0-3 for each category. (0 being not a problem, 3 being severe problem). Scores from all sub scales were added (scoring 0-45 for Irritability subscale, 0-48 for Lethargy subscale, 0-21 for stereotypy scale, 0-48 for hyperactivity sub-scale, and 0-12 for inappropriate speech sub-scale) to obtain a total score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Divalproex Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive the study drug, divalproex sodium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex sodium</intervention_name>
    <description>Study drug.</description>
    <arm_group_label>Divalproex Sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Meets DSM-IV, ADI, and ADOS criteria for autistic disorder&#xD;
&#xD;
        Age 5-17.&#xD;
&#xD;
        Outpatients&#xD;
&#xD;
        Parent/legal guardian signing informed consent, and assent documented for patient with&#xD;
        demonstrated capacity to provide it.&#xD;
&#xD;
        Sexually active females of childbearing potential must use an acceptable method of birth&#xD;
        control (oral contraceptive medications [the administration of which must be supervised by&#xD;
        a parent or guardian], IUD, depot medication or tubal ligation) and have a negative serum&#xD;
        pregnancy test prior to entry into the study.&#xD;
&#xD;
        Subject scores at least &quot;4&quot; (moderately ill) on the Clinical Global Impression-Severity&#xD;
        Scale for Autistic Disorder (CGI-AD).&#xD;
&#xD;
        Subject meets the following criteria at pre-study diagnostic assessment and baseline&#xD;
        assessment: OAS-M 13 or ABC-Irritability Subscale 18 (raw scores).&#xD;
&#xD;
        Subjects with history of seizures, who have been seizure-free for 6 months on a stable dose&#xD;
        of anticonvulsant medication other than divalproex sodium or related formulations (e.g.,&#xD;
        depakene). Non-medicated subjects with a history of seizures who have been seizure-free for&#xD;
        6 months. Subjects with abnormal EEG but no clinical seizures.&#xD;
&#xD;
        State exclusion criteria for enrollment in study:&#xD;
&#xD;
        Subjects who are pregnant or nursing mothers. Sexually active women of childbearing&#xD;
        potential who are not using adequate birth control measures (detailed above in inclusion&#xD;
        criteria).&#xD;
&#xD;
        Subjects with overall adaptive behavior scores below the age of two years on the Vineland&#xD;
        Adaptive Behavior Rating Scale.&#xD;
&#xD;
        Subjects with active or unstable epilepsy.&#xD;
&#xD;
        Subjects with any of the following past or present mental disorders: schizophrenia,&#xD;
        schizoaffective disorder or organic mental disorders.&#xD;
&#xD;
        Subjects who are a serious suicidal risk.&#xD;
&#xD;
        Subjects with clinically significant or unstable medical illness that would contraindicate&#xD;
        participation in the study, including hematopoietic or cardiovascular disease,&#xD;
        pancreatitis, liver toxicity, and polycystic ovary syndrome.&#xD;
&#xD;
        Subjects reporting history of encephalitis, phenylketonuria, tuberous sclerosis, fragile X&#xD;
        syndrome, anoxia during birth, pica, neurofibromatosis, hypomelanosis of Ito,&#xD;
        hypothyroidism, Duchenne muscular dystrophy, and maternal rubella.&#xD;
&#xD;
        Patients with history of the following:&#xD;
&#xD;
        gastrointestinal, liver, or kidney, or other known conditions which will presently&#xD;
        interfere presently with the absorption, distribution, metabolism, or excretion of drugs;&#xD;
        cerebrovascular disease or brain trauma; clinically significant unstable endocrine&#xD;
        disorder, such as hypo- or hyperthyroidism; recent history or presence of any form of&#xD;
        malignancy&#xD;
&#xD;
        Treatment within the previous 30 days with any drug known to a well-defined potential for&#xD;
        toxicity to a major organ&#xD;
&#xD;
        Subjects with clinically significant abnormalities in laboratory tests or physical exam.&#xD;
&#xD;
        Subjects likely to require ECT or any other psychotropic medication during the study,&#xD;
        unless otherwise permitted.&#xD;
&#xD;
        Subjects unable to tolerate taper from psychoactive medication if necessary.&#xD;
&#xD;
        Subjects with a history of hypersensitivity or severe side effects associated with the use&#xD;
        of divalproex sodium, or other an ineffective prior therapeutic trial of divalproex sodium&#xD;
        (serum levels within range of 50-100 ug/ml for 6 weeks).&#xD;
&#xD;
        Subjects who have received any of the following interventions within the prescribed period&#xD;
        before starting treatment:&#xD;
&#xD;
        investigational drugs within the previous 30 days; depot neuroleptic medication;&#xD;
        psychotropic drugs not permitted for concurrent use in the study within the previous seven&#xD;
        days; fluoxetine within the previous five weeks.&#xD;
&#xD;
        Subjects who have begun any new alternative non-medication treatments, such as diet,&#xD;
        vitamins, and psychosocial therapy, within the previous three months.&#xD;
&#xD;
        Subjects with any organic or systemic disease or patients who require a therapeutic&#xD;
        intervention, not otherwise specified, which would confound the evaluation of the safety of&#xD;
        the study medication.&#xD;
&#xD;
        Subjects who reside in a remote geographical area who do not have regular access to&#xD;
        transportation to the clinical facility.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hollander</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>May 29, 2018</results_first_submitted>
  <results_first_submitted_qc>December 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2018</results_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Eric Hollander</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>autism</keyword>
  <keyword>aggression</keyword>
  <keyword>irritability</keyword>
  <keyword>divalproex sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.&#xD;
Placebo: Placebo comparator.</description>
        </group>
        <group group_id="P2">
          <title>Divalproex Sodium</title>
          <description>Subjects will receive the study drug, divalproex sodium.&#xD;
Divalproex sodium: Study drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.&#xD;
Placebo: Placebo comparator.</description>
        </group>
        <group group_id="B2">
          <title>Divalporex Sodium</title>
          <description>Subjects will receive the study drug, divalproex sodium.&#xD;
Divalproex sodium: Study drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <description>Subjects were either diagnosed with Autistic Disorder or Asperger's syndrome</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Autistic Disorder</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asperger's Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Improvement on the Clinical Global Impression</title>
        <description>The CGI-I is a 7-point improvement scale. Ratings of 1 or 2 (responders) indicate a substantial reduction in symptoms. A rating of 3 (minimally improved) on the CGI is defined as a slight symptomatic improvement that is not deemed clinically significant; patients with such an improvement were not considered responders. Two versions of this test were used, one focused on irritability (primary outcome measure) and a general version CGI-I-autism focused on all symptoms including core symptom domains. The CGI-I irritability took into consideration the scores from the ABC-Irritability subscale, the OAS-M aggression and irritability subscales and information from open-ended questioning related to the degree of interference, nature, and range of behavioral problems at school and at home</description>
        <time_frame>Baseline to end of study (week 15)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.&#xD;
Placebo: Placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Divalproex Sodium</title>
            <description>Subjects will receive the study drug, divalproex sodium.&#xD;
Divalproex sodium: Study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Improvement on the Clinical Global Impression</title>
          <description>The CGI-I is a 7-point improvement scale. Ratings of 1 or 2 (responders) indicate a substantial reduction in symptoms. A rating of 3 (minimally improved) on the CGI is defined as a slight symptomatic improvement that is not deemed clinically significant; patients with such an improvement were not considered responders. Two versions of this test were used, one focused on irritability (primary outcome measure) and a general version CGI-I-autism focused on all symptoms including core symptom domains. The CGI-I irritability took into consideration the scores from the ABC-Irritability subscale, the OAS-M aggression and irritability subscales and information from open-ended questioning related to the degree of interference, nature, and range of behavioral problems at school and at home</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores</title>
        <description>The Aberrant Behavior Checklist is designed to objectively identify five behavior sub scales through observation by the primary caregiver: irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech. The ABC was filled out by parents on a scale from 0-3 for each category. (0 being not a problem, 3 being severe problem). Scores from all sub scales were added (scoring 0-45 for Irritability subscale, 0-48 for Lethargy subscale, 0-21 for stereotypy scale, 0-48 for hyperactivity sub-scale, and 0-12 for inappropriate speech sub-scale) to obtain a total score.</description>
        <time_frame>Baseline and End of Study (week 15)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects in this arm will receive a placebo comparative to the study drug divalporex sodium.&#xD;
Placebo: Placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Divalproex Sodium</title>
            <description>Subjects will receive the study drug, divalproex sodium.&#xD;
divalproex sodium: Study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores</title>
          <description>The Aberrant Behavior Checklist is designed to objectively identify five behavior sub scales through observation by the primary caregiver: irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech. The ABC was filled out by parents on a scale from 0-3 for each category. (0 being not a problem, 3 being severe problem). Scores from all sub scales were added (scoring 0-45 for Irritability subscale, 0-48 for Lethargy subscale, 0-21 for stereotypy scale, 0-48 for hyperactivity sub-scale, and 0-12 for inappropriate speech sub-scale) to obtain a total score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="7.81"/>
                    <measurement group_id="O2" value="20.3" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="6.67"/>
                    <measurement group_id="O2" value="17.7" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks on treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.&#xD;
Placebo: Placebo comparator.</description>
        </group>
        <group group_id="E2">
          <title>Divalproex Sodium</title>
          <description>Subjects will receive the study drug, divalproex sodium.&#xD;
Divalproex sodium: Study drug.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypersomnolence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gian</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Hollander</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-4287</phone>
      <email>eholland@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

